Trials / Recruiting
RecruitingNCT06058988
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab deruxtecan | All participants will receive T-DXd prior to indicated brain tumor resection/biopsy |
Timeline
- Start date
- 2023-09-22
- Primary completion
- 2027-09-22
- Completion
- 2027-09-22
- First posted
- 2023-09-28
- Last updated
- 2026-02-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06058988. Inclusion in this directory is not an endorsement.